PUBLIC COMPANY
saveSpringWorks Therapeutics Inc
updated 12d ago
community read0 votes
pipeline
5
marketed
2
phase 3
0
catalysts ytd
1
approvals ytd
1
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Phase 11Phase 22Marketed1Unknown
Marketed
mirdametinib ODT
Neurofibromatoses Type I (Von Recklinghausen's Disease)
Marketednirogacestat hydrobromide
Desmoid Tumors
Phase 2mirdametinib
Non-Small Cell Lung Cancer
Dual specificity mitogen-activated protein kinase kinase 1Dual specificity mitogen-activated protein kinase kinase 2
Phase 1SW-682
Malignant Mesothelioma
drugOGSIVEO
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Aura, Schrödinger trim workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Beeline ups its Series A round for immune drug workThe company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.biopharma_dive · 1mo ago
- Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60%As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 7mo ago
- Fierce Biotech Fundraising Tracker '26: Vaderis nets $152M series B; Epicrispr adds $90MThe Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.fiercebiotech · 7mo ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that